SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia.
about
Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia.Potent mechanism-based sirtuin-2-selective inhibition by an in situ-generated occupant of the substrate-binding site, "selectivity pocket" and NAD+-binding site.Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines
P2860
SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia.
@en
type
label
SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia.
@en
prefLabel
SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia.
@en
P2093
P2860
P356
P1433
P1476
SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia.
@en
P2093
Ailing Deng
Qiaoyang Ning
Yaojie Liang
P2860
P2888
P356
10.1038/SREP27694
P407
P577
2016-06-13T00:00:00Z